GLP-1-induced gastroparesis
What the FDA labels record as adverse events, each one tied back to the evidence it came from.
Definition
Gastric emptying delayed enough to cause persistent nausea, vomiting or food sitting undigested. A 2023 JAMA case-control study (PMID 37335445) found a 3.7-fold increase in clinically diagnosed gastroparesis against bupropion-naltrexone. Risk climbs with higher doses, faster titration and pre-existing diabetic autonomic neuropathy; symptoms usually settle within four to eight weeks of reducing or stopping.
GLP Watchdog writes these definitions from FDA labels and peer-reviewed PubMed literature. Not one of them is an AI-generated summary.
Other terms under Side effects
Where the evidence lives
- Side-effect timeline tool
- The full GLP-1 glossary (149 terms, 8 categories)
- Research articles — written from primary sources
- Tools and calculators
- Compare GLP-1 telehealth providers